CDEK
← All drugs Report issue

glycopyrrolate

Small moleculeexperimental

Clinical trial activity

14 trials · 9 clinical orgs · 0 marketing orgs

Phase 1
2
Phase 2
11
Phase 3
1
Phase 4
1

Earliest trial started May 1, 2009 (NCT00893971)

Timeline

2000s

  1. Jan 1, 2009

    Earliest Phase 1 Sponsor(trial)

2010s

  1. Jan 1, 2010

    Earliest Phase 2 Sponsor(trial)

2020s

  1. Jan 1, 2023

    Earliest Phase 3 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Also known as

  • chf5259
  • chf 5259
  • chf5992
  • pt003

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05970263Phase 4Jan 15, 2024AstraZeneca, IQVIA
NCT06643078Phase 3Dec 11, 2023Haisco Pharmaceutical
NCT06619210Phase 2Jan 12, 2022Haisco Pharmaceutical, Sichuan University
NCT02680197Phase 2Feb 29, 2016Chiesi, Institut für Atemwegsforschung GmbH
NCT03004495Phase 1Jan 1, 2016Chiesi, IQVIA
NCT02296411Phase 2Nov 1, 2014Chiesi
NCT02189577Phase 2Jun 1, 2014Chiesi, University of London
NCT02127866Phase 2Apr 1, 2014Chiesi, University of Manchester
NCT01587079Phase 2Apr 1, 2012Pearl Therapeutics
NCT01584505Phase 2Apr 1, 2012Chiesi
NCT01349816Phase 2Jun 1, 2011Pearl Therapeutics
NCT01349803Phase 2May 1, 2011Pearl Therapeutics
NCT01085045Phase 2Mar 1, 2010Pearl Therapeutics
NCT00893971Phase 1May 1, 2009Pearl Therapeutics
Showing 14 of 14 trials
Page 1 / 1

Organizations

Research & Development (9)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
ChiesiFor profit6622012
Pearl TherapeuticsFor profit5522009
Haisco PharmaceuticalFor profit2222022
IQVIAFor profit2022016
AstraZenecaFor profit1112024
Institut für Atemwegsforschung GmbHAcademic/Hospital1012016
Sichuan UniversityAcademic/Hospital1012022
University of LondonAcademic/Hospital1012014
University of ManchesterAcademic/Hospital1012014
9 organizations
Page 1 / 1